Randomized Phase I Trial of Two Different Combination Foscarnet and Ganciclovir Chronic Maintenance Therapy Regimens for AIDS Patients with Cytomegalovirus Retinitis: AIDS Clinical Trials Group Protocol 151

AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis. Each regimen used lower we...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1994-07, Vol.170 (1), p.189-193
Main Authors: Jacobson, Mark A., Kramer, Francoise, Bassiakos, Yiannis, Hooton, Thomas, Polsky, Bruce, Geheb, Heidi, O'Donnell, James J., Walker, John D., Korvick, Joyce A., van der Horst, Charles
Format: Article
Language:English
Subjects:
Adolescent
Adult
AIDS
AIDS-Related Opportunistic Infections - drug therapy
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antivirals
Biological and medical sciences
Cell culture techniques
Cells, Cultured
Clinical Protocols
Concise Comunications
Cytomegalovirus
Cytomegalovirus Infections - complications
Cytomegalovirus Infections - drug therapy
Drug Therapy, Combination
Experimentation
Female
Foscarnet - therapeutic use
Ganciclovir - therapeutic use
Grade 3
Humans
Male
Medical sciences
Monoclonal antibodies
Neutropenia
Pharmacology. Drug treatments
Retinitis
Retinitis - complications
Retinitis - drug therapy
Urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis. Each regimen used lower weekly cumulative doses of each drug than standard monotherapy maintenance treatment regimens. Dose-limiting toxicity attributable to foscarnet occurred in only 2 (7%) of29 evaluatable patients, and no patients experienced dose-limiting nephrotoxicity. Although absolute neutrophil counts
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/170.1.189